Insider Selling: Alphatec (NASDAQ:ATEC) Major Shareholder Sells 250,000 Shares of Stock

by · The Markets Daily

Alphatec Holdings, Inc. (NASDAQ:ATEC – Get Free Report) major shareholder Squadron Capital Llc sold 250,000 shares of the firm’s stock in a transaction that occurred on Monday, November 24th. The stock was sold at an average price of $20.62, for a total transaction of $5,155,000.00. Following the sale, the insider owned 10,895,045 shares of the company’s stock, valued at $224,655,827.90. This represents a 2.24% decrease in their position. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Large shareholders that own more than 10% of a company’s stock are required to disclose their sales and purchases with the SEC.

Squadron Capital Llc also recently made the following trade(s):

  • On Wednesday, November 12th, Squadron Capital Llc sold 250,000 shares of Alphatec stock. The stock was sold at an average price of $20.80, for a total value of $5,200,000.00.

Alphatec Trading Up 5.8%

Shares of NASDAQ:ATEC traded up $1.20 during midday trading on Tuesday, reaching $21.83. 2,887,048 shares of the company’s stock were exchanged, compared to its average volume of 2,130,099. The stock has a market cap of $3.24 billion, a price-to-earnings ratio of -19.32 and a beta of 1.17. Alphatec Holdings, Inc. has a fifty-two week low of $8.69 and a fifty-two week high of $22.00. The firm’s 50 day simple moving average is $16.59 and its two-hundred day simple moving average is $14.26. The company has a debt-to-equity ratio of 23.22, a current ratio of 2.88 and a quick ratio of 1.77.

Alphatec (NASDAQ:ATEC – Get Free Report) last announced its quarterly earnings results on Thursday, October 30th. The medical technology company reported $0.03 earnings per share for the quarter, beating analysts’ consensus estimates of ($0.06) by $0.09. The company had revenue of $196.50 million for the quarter, compared to analyst estimates of $182.78 million. During the same quarter in the prior year, the business earned ($0.28) earnings per share. Alphatec’s revenue was up 30.4% on a year-over-year basis. Alphatec has set its FY 2025 guidance at EPS. As a group, sell-side analysts forecast that Alphatec Holdings, Inc. will post -1.08 EPS for the current fiscal year.

Wall Street Analyst Weigh In

Several equities analysts have weighed in on ATEC shares. Morgan Stanley lifted their target price on Alphatec from $16.00 to $21.00 and gave the company an “equal weight” rating in a research report on Monday, November 10th. Wall Street Zen upgraded shares of Alphatec from a “hold” rating to a “buy” rating in a report on Saturday, October 18th. Stifel Nicolaus assumed coverage on shares of Alphatec in a research report on Tuesday, October 28th. They issued a “buy” rating and a $20.00 price target for the company. Lake Street Capital set a $25.00 price objective on Alphatec and gave the stock a “buy” rating in a research report on Friday, October 31st. Finally, Piper Sandler reissued an “overweight” rating and set a $25.00 target price (up from $20.00) on shares of Alphatec in a research note on Friday, October 31st. Nine equities research analysts have rated the stock with a Buy rating, one has issued a Hold rating and one has issued a Sell rating to the stock. Based on data from MarketBeat.com, the stock currently has an average rating of “Moderate Buy” and a consensus target price of $22.00.

Read Our Latest Research Report on Alphatec

Institutional Inflows and Outflows

Institutional investors and hedge funds have recently made changes to their positions in the business. Creative Planning boosted its stake in Alphatec by 0.9% in the third quarter. Creative Planning now owns 58,654 shares of the medical technology company’s stock valued at $853,000 after acquiring an additional 534 shares in the last quarter. Valeo Financial Advisors LLC boosted its position in shares of Alphatec by 2.1% in the 3rd quarter. Valeo Financial Advisors LLC now owns 41,296 shares of the medical technology company’s stock valued at $600,000 after purchasing an additional 846 shares during the period. Norden Group LLC increased its position in Alphatec by 2.6% during the third quarter. Norden Group LLC now owns 36,676 shares of the medical technology company’s stock worth $533,000 after buying an additional 939 shares during the period. Arizona State Retirement System lifted its stake in Alphatec by 2.8% in the third quarter. Arizona State Retirement System now owns 34,603 shares of the medical technology company’s stock valued at $503,000 after buying an additional 949 shares during the last quarter. Finally, Ameritas Investment Partners Inc. boosted its holdings in shares of Alphatec by 8.8% in the second quarter. Ameritas Investment Partners Inc. now owns 11,845 shares of the medical technology company’s stock valued at $131,000 after acquiring an additional 955 shares during the period. 66.35% of the stock is owned by institutional investors and hedge funds.

About Alphatec

(Get Free Report)

Alphatec Holdings, Inc, a medical technology company, designs, develops, and advances technologies for the surgical treatment of spinal disorders in the United States and internationally. It manufactures and sells implants and instruments through third-party suppliers. The company offers Alpha InformatiX product platform, including EOS imaging system that provides full-body imaging; VEA alignment mobile application, which leverages EOS technology to more quickly quantify alignment parameters on a mobile device; SafeOp Neural InformatiX System that automates electromyographic and somatosensory evoked potential monitoring; and Valence, an intra-operative system that integrates navigation and robotics into spine procedures, as well as Sigma Prone TransPsoas (PTP) Access and PTP Patient Positioning Systems.

Featured Stories